Status:
COMPLETED
Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)
Lead Sponsor:
Osaka University
Conditions:
Dementia With Lewy Bodies (DLB)
Eligibility:
All Genders
60-85 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.
Eligibility Criteria
Inclusion
- DLB patients:
- who fulfill the diagnostic criteria of DLB
- 60 to 85 years old
- right-handed
- Clinical Dementia Rating (CDR) ≧ 0.5
- Mini Mental State Examination (MMSE) score from 10 to 26
- Normal Controls:
- who are independent
- who have no subjective or objective cognitive impairment
- 60 to 85 years old
- right-handed
- MMSE score over 24
Exclusion
- DLB patients:
- who have diabetes mellitus
- who have pathological change on MRI other than brain atrophy
- who have complication or history of dementia other than DLB, psychiatric disease, and physical disorder that affect brain function
- who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety
- who have severe digestive ulcus
- who have severe bronchitic asthma or obstructive lung disease
- who have no caregiver who knows patient's condition well
- Normal Controls:
- who have diabetes mellitus
- who have taken donepezil before
- who have abnormal findings on MRI
- who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00776347
Start Date
October 1 2008
End Date
February 1 2015
Last Update
October 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka University Hospital
Suita, Osaka, Japan, 565-0871